Caribou Biosciences, Inc. (CRBU) Dividend History

Caribou Biosciences, Inc. is a biotechnology company focused on developing gene-editing technologies using CRISPR-Cas3 and other CRISPR-based tools. Founded in 2011, it specializes in precision gene editing for applications in agriculture, human therapeutics, and industrial biotechnology. The company's platform aims to enable more efficient, accurate, and versatile genetic modifications to address various biological challenges.

2929 7th Street, Suite 105, Berkeley, CA, 94710
Phone: 510-982-6030
Website: https://www.cariboubio.com

Dividend History

Caribou Biosciences, Inc. currently does not pay dividends

Company News

  • Caribou Biosciences to Participate in the BofA Securities 2025 Health Care Conference

    Caribou Biosciences, a clinical-stage CRISPR genome-editing biopharmaceutical company, announced a strategic pipeline prioritization with a focus on its CB-010 and CB-011 oncology programs. The company expects this move to extend its cash runway by one year into H2 2027.

    GlobeNewswire Inc.
  • Cracking The Code: Understanding Analyst Reviews For Caribou Biosciences

    During the last three months, 5 analysts shared their evaluations of Caribou Biosciences (NASDAQ:CRBU), revealing diverse outlooks from bullish to bearish. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 1 0 0 0 Last 30D 1 0 0 0 0 1M Ago 2 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 1 1 0 0 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $19.0, a high estimate of $24.00, and a low estimate of $9.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 13.64%. Analyzing Analyst Ratings: A Detailed Breakdown A comprehensive examination of how financial experts perceive Caribou Biosciences is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Robert Burns HC Wainwright & Co. Lowers Buy $9.00 $24.00 Asthika Goonewardene Truist Securities Maintains Buy $19.00 $19.00 Robert Burns HC Wainwright & Co. Maintains Buy $24.00 - Robert Burns HC Wainwright & Co. Raises Buy $24.00 $23.00 Luca Issi RBC Capital Maintains Outperform $19.00 - Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their ...Full story available on Benzinga.com

    Benzinga
  • Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates

    Caribou Biosciences (CRBU) delivered earnings and revenue surprises of -17.95% and 19.03%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

    Zacks Investment Research
    Featured Companies: EXAS
  • Why Caribou Biosciences Stock Is Crashing Today

    Investors didn't like the clinical-stage biotech's Q4 update for one key reason.

    The Motley Fool
Page data last updated 07/23/2025 06:08:44 UTC